Matches in Wikidata for { <http://www.wikidata.org/entity/Q66044342> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q66044342 description "clinical trial" @default.
- Q66044342 description "ensayu clínicu" @default.
- Q66044342 description "klinisch onderzoek" @default.
- Q66044342 description "клінічне випробування" @default.
- Q66044342 name "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer" @default.
- Q66044342 name "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation" @default.
- Q66044342 type Item @default.
- Q66044342 label "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer" @default.
- Q66044342 label "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation" @default.
- Q66044342 prefLabel "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer" @default.
- Q66044342 prefLabel "Platinum and Polyadenosine 5'Diphosphoribose Polymerisation" @default.
- Q66044342 P1132 Q66044342-0EEE8CBD-9A12-4231-ABE3-6592C2CFC9A0 @default.
- Q66044342 P1476 Q66044342-030FA73F-3151-4C92-A00C-30BF5AB268E0 @default.
- Q66044342 P17 Q66044342-928B6E11-486A-4CFC-99BB-6A6DCF8E7310 @default.
- Q66044342 P1813 Q66044342-7B3E8929-BB2F-4A0B-B11A-9CAD52755442 @default.
- Q66044342 P2899 Q66044342-9A1C8402-2BFD-4C11-8AF8-70A186ED6B78 @default.
- Q66044342 P3098 Q66044342-B23C3CB6-9548-41F7-AC38-C7E28FC65BDB @default.
- Q66044342 P31 Q66044342-92600AFD-E870-4202-8F07-C9958836BF20 @default.
- Q66044342 P4135 Q66044342-62964E42-CE11-470D-9A79-D38B3069E214 @default.
- Q66044342 P4844 Q66044342-1AB4977D-AE3C-46F3-AAAA-ADC65B173666 @default.
- Q66044342 P4844 Q66044342-26E8BA65-114A-4965-931A-9CE389AC27B6 @default.
- Q66044342 P580 Q66044342-4615C9FA-1601-46D3-B95A-56A54455F1D9 @default.
- Q66044342 P582 Q66044342-E264045C-55F3-4932-98FD-520C2AFD8F89 @default.
- Q66044342 P6099 Q66044342-177CCFDA-1F32-4956-A185-90B111FA6E89 @default.
- Q66044342 P6099 Q66044342-B2567449-9BB1-4DFF-985C-803B608C062A @default.
- Q66044342 P8363 Q66044342-D2A4D027-4ABC-4824-8FE7-8AA2DF549A51 @default.
- Q66044342 P1132 "+527" @default.
- Q66044342 P1476 "Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA." @default.
- Q66044342 P17 Q145 @default.
- Q66044342 P1813 "PARTNER" @default.
- Q66044342 P2899 "+16" @default.
- Q66044342 P3098 "NCT03150576" @default.
- Q66044342 P31 Q30612 @default.
- Q66044342 P4135 "+70" @default.
- Q66044342 P4844 Q415588 @default.
- Q66044342 P4844 Q423762 @default.
- Q66044342 P580 "2016-05-01T00:00:00Z" @default.
- Q66044342 P582 "2022-01-01T00:00:00Z" @default.
- Q66044342 P6099 Q42824440 @default.
- Q66044342 P6099 Q42824827 @default.
- Q66044342 P8363 Q78089383 @default.